Evaluation Of Effectiveness And Safety Of Oral Bepotastine In The Management Of Chronic Urticaria

ABSTRACT

Introduction: Nearly 20% of the total population suffer from urticaria for a minimum of one episode during the entire lifetime.Second-generation antihistamines are preferred in majority cases of urticaria.Objective: The present survey was undertaken in pursuit of analyzing the effectiveness and safety of bepotastine in thetreatment of chronic urticaria (CU).Materials and Methods: This was a retrospective questionnaire-based survey. Doctors were identified from four directionalzones of the country, and each was given prevalidated questionnaire booklets. Clinical response was evaluated by urticariaactivity score (UAS) at baseline (D0), day 14 (D14), and day 28 (D28). All the adverse effects were monitored for severity.Specifically, sedation was closely monitored for its occurrence and severity.Results: A total of 50 doctors completed the survey involving 226 patients. The mean UAS score at D0/baseline was 3.47which reduced to 1.71 at D14 and 0.73 at D28. 78 patients were having UAS score in the range of 1–2, 89 patients in 3–4, and59 patients in the range of 5–6 at D0. 59 patients were encountered in Grade 5–6 at D0, which reduced to 45 patients at D14and 29 patients at D28, while 89 patients in score range 3–4 at D0 reduced to 68 at D14 and 38 at D28. Sedation was reportedin only 15 patients (6.6%) that too majority had mild sedation, rated in sedation scale range of 0–5.Conclusion: The present survey indicates that bepotastine is efficacious and safe in the management of CU.